Prospeo
Hero Section BackgroundHero Section Background
Arvinas

Arvinas Email Formats

Biotechnology ResearchFlag of USNew Haven, Connecticut, United States201-500 Employees

Arvinas Email Formats

Arvinas uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@arvinas.com), used 84.6% of the time.

FormatExamplePercentage
{first initial}.{last name}
j.doe@arvinas.com
84.6%
{first name}.{last name}
john.doe@arvinas.com
12.2%
{2char}
{2char}@arvinas.com
2.1%

Key Contacts at Arvinas

Flag of US

Deborah Kroeger

Senior Director, Talent Acquisition

Flag of US

Will Kattell

Associate Director, Talent Acquisition

Flag of US

Joseph Reo

Senior Director

Flag of US

Rushad E. Karanjawala

Director Ethics & Compliance

Flag of US

Milky Florent

Executive Director, Regulatory Affairs

Flag of US

Tim Bye

Senior Director, Commercial Operations

Flag of US

Stacey Versavel

Senior Medical Director, Neurology, Medical Affairs

Flag of US

Joseph Sciacchitano

Us Head, Senior Director Patient Support Services | Market Access

Flag of US

Christine Edwards

Associate Director, Talent Acquisition

Flag of US

Cathy Consolo

Executive Director National Payer Accounts

Company overview

Headquarters395 Winchester Ave., 5 Science Park, New Haven, Connecticut 06511, US
Phone number+12035351456
Website
NAICS541714
SIC283
Founded2013
Employees201-500
Socials

About Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG

Employees by Management Level

Total employees: 201-500

Seniority

Employees

Director
Entry
Senior

Employees by Department

Arvinas has 174 employees across 17 departments.

Departments

Number of employees

Funding Data

Explore Arvinas's funding history, including investment rounds, total capital raised, and key backers.

Funding Date
Round
Amount
Link to Article
2023-12-2714$350,000,000
2025-09-1514N/A

Funding Insights

$350,000,000

Total funding amount

2

Number of funding rounds

Arvinas Tech Stack

Discover the technologies and tools that power Arvinas's digital infrastructure, from frameworks to analytics platforms.

WP Rocket

WP Rocket

Caching

Swiper

Swiper

JavaScript libraries

jQuery UI

jQuery UI

JavaScript libraries

Google Maps

Google Maps

Maps

Hello Elementor

Hello Elementor

WordPress themes

Elementor

Elementor

Page builders

Microsoft 365

Microsoft 365

Email

jQuery Migrate

jQuery Migrate

JavaScript libraries

jQuery

jQuery

JavaScript libraries

Apple iCloud Mail

Apple iCloud Mail

Webmail

PHP

PHP

Programming languages

HSTS

HSTS

Security

Frequently asked questions

Arvinas is located in New Haven, Connecticut, US.
You can reach Arvinas at +12035351456.
Arvinas was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.
Arvinas has approximately 201-500 employees. The company continues to grow its workforce to support its business operations and expansion.
Arvinas has raised a total of $350,000,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.

4.8

40,000 users

top 50
high performer
most used
tier 1 accuracy

Build leads list with verified emails & mobiles